Riociguat

Adempas (riociguat) is a small molecule pharmaceutical. Riociguat was first approved as Adempas on 2013-10-08. It is used to treat pulmonary hypertension in the USA. It has been approved in Europe to treat pulmonary hypertension. It is known to target guanylate cyclase soluble subunit alpha-1, guanylate cyclase soluble subunit beta-1, and guanylate cyclase soluble subunit alpha-2. Adempas's patents are valid until 2034-02-18 (FDA).